6CFD | pdb_00006cfd

ADEP4 bound to E. faecium ClpP


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.57 Å
  • R-Value Free: 
    0.209 (Depositor), 0.213 (DCC) 
  • R-Value Work: 
    0.175 (Depositor), 0.179 (DCC) 
  • R-Value Observed: 
    0.176 (Depositor) 

Starting Model: experimental
View more details

wwPDB Validation 3D Report Full Report

Validation slider image for 6CFD

Ligand Structure Quality Assessment 


This is version 1.4 of the entry. See complete history

Literature

In VivoandIn VitroEffects of a ClpP-Activating Antibiotic against Vancomycin-Resistant Enterococci.

Brown Gandt, A.Griffith, E.C.Lister, I.M.Billings, L.L.Han, A.Tangallapally, R.Zhao, Y.Singh, A.P.Lee, R.E.LaFleur, M.D.

(2018) Antimicrob Agents Chemother 62

  • DOI: https://doi.org/10.1128/AAC.00424-18
  • Primary Citation Related Structures: 
    6CFD

  • PubMed Abstract: 

    Antibiotics with novel bactericidal mechanisms of action are urgently needed. The antibiotic acyldepsipeptide 4 (ADEP4) activates the ClpP protease and causes cells to self-digest. The effects of ADEP4 and ClpP activation have not been characterized sufficiently for the enterococci, which are important pathogens known for high levels of acquired and intrinsic antibiotic resistance. In the present study, ADEP4 was found to be potently active against both Enterococcus faecalis and Enterococcus faecium , with MIC 90 s of 0.016 μg/ml and 0.031 μg/ml, respectively. ClpP purified from E. faecium was found to bind ADEP4 in a surface plasmon resonance analysis, and ClpP activation by ADEP4 was demonstrated biochemically with a β-casein digestion assay. In addition, E. faecium ClpP was crystallized in the presence of ADEP4, revealing ADEP4 binding to ClpP in the activated state. These results confirm that the anti-enterococcal activity of ADEP4 occurs through ClpP activation. In killing curve assays, ADEP4 was found to be bactericidal against stationary-phase vancomycin-resistant E. faecalis (VRE) strain V583, and resistance development was prevented when ADEP4 was combined with multiple classes of approved antibiotics. ADEP4 in combination with partnering antibiotics also eradicated mature VRE biofilms within 72 h of treatment. Biofilm killing with ADEP4 antibiotic combinations was superior to that with the clinically used combinations ampicillin-gentamicin and ampicillin-daptomycin. In a murine peritoneal septicemia model, ADEP4 alone was as effective as ampicillin. ADEP4 coadministered with ampicillin was significantly more effective than either drug alone. These data suggest that ClpP-activating antibiotics may be useful for treating enterococcal infections.


  • Organizational Affiliation
    • Arietis Pharma, Boston, Massachusetts, USA.

Macromolecule Content 

  • Total Structure Weight: 336.3 kDa 
  • Atom Count: 20,070 
  • Modeled Residue Count: 2,548 
  • Deposited Residue Count: 2,940 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
ATP-dependent Clp protease proteolytic subunit210Enterococcus faeciumMutation(s): 0 
Gene Names: 
EC: 3.4.21.92
UniProt
Find proteins for Q3XX76 (Enterococcus faecium (strain ATCC BAA-472 / TX0016 / DO))
Explore Q3XX76 
Go to UniProtKB:  Q3XX76
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ3XX76
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Ligands 2 Unique
IDChains Name / Formula / InChI Key2D Diagram3D Interactions
EZA
(Subject of Investigation/LOI)

Query on EZA



Download:Ideal Coordinates CCD File
BA [auth I]
EA [auth L]
GA [auth M]
IA [auth N]
KA [auth S]
BA [auth I],
EA [auth L],
GA [auth M],
IA [auth N],
KA [auth S],
MA [auth T],
P [auth A],
S [auth C],
U [auth D],
W [auth E],
Y [auth F]
N-[(6aS,12S,15aS,17R,21R,23aS)-17,21-dimethyl-6,11,15,20,23-pentaoxooctadecahydro-2H,6H,11H,15H-pyrido[2,1-i]dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13]oxatetraazacyclohexadecin-12-yl]-3,5-difluoro-Nalpha-[(2E)-hept-2-enoyl]-L-phenylalaninamide
C39 H52 F2 N6 O8
BAEUBYUDIYWBPI-AIRHAPKHSA-N
MPD

Query on MPD



Download:Ideal Coordinates CCD File
AA [auth I]
CA [auth K]
DA [auth L]
FA [auth M]
HA [auth N]
AA [auth I],
CA [auth K],
DA [auth L],
FA [auth M],
HA [auth N],
JA [auth S],
LA [auth T],
O [auth A],
Q [auth B],
R [auth C],
T [auth D],
V [auth E],
X [auth F],
Z [auth G]
(4S)-2-METHYL-2,4-PENTANEDIOL
C6 H14 O2
SVTBMSDMJJWYQN-YFKPBYRVSA-N

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.57 Å
  • R-Value Free:  0.209 (Depositor), 0.213 (DCC) 
  • R-Value Work:  0.175 (Depositor), 0.179 (DCC) 
  • R-Value Observed: 0.176 (Depositor) 
Space Group: P 1 21 1
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 97.395α = 90
b = 202.166β = 102.69
c = 97.385γ = 90
Software Package:
Software NamePurpose
REFMACrefinement
HKL-2000data scaling
PDB_EXTRACTdata extraction
HKL-2000data reduction
PHASERphasing

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

& Funding Information

Deposition Data


Funding OrganizationLocationGrant Number
National Institutes of Health/National Institute Of Allergy and Infectious Diseases (NIH/NIAID)United States5R44AI122426-02

Revision History  (Full details and data files)

  • Version 1.0: 2018-05-16
    Type: Initial release
  • Version 1.1: 2018-06-06
    Changes: Data collection, Database references
  • Version 1.2: 2018-08-08
    Changes: Data collection, Database references
  • Version 1.3: 2019-12-11
    Changes: Author supporting evidence
  • Version 1.4: 2023-10-04
    Changes: Data collection, Database references, Refinement description